Core Viewpoint - The company achieved significant revenue growth in the first half of 2025, with a reported revenue of 130 million, representing a year-on-year increase of 61.80% [1] Group 1: Financial Performance - The company reported a revenue of 130 million in the first half of 2025, marking a 61.80% increase compared to the previous year [1] Group 2: Product Development and Commercialization - The company is advancing its Commercialization 2.0 upgrade, with two commercialized products, Ouyoubi® and Dipate®, experiencing rapid sales growth [1] - The company is preparing for the market launch of Alectinib Injection (Ounalin®), expanding its product line to cover early and late-stage breast cancer [1] Group 3: Innovation and Regulatory Progress - Significant progress has been made with two core innovative products, with the non-invasive treatment for cervical precancerous lesions, APL-1702, undergoing its second round of technical review by the National Medical Products Administration [1] - Haikewei® has been approved as the first blue light imaging agent in the domestic bladder cancer field, marking the beginning of a new era in blue light diagnosis and treatment in China [1] - Competitive pipeline products APL-2302 (potential best-in-class USP1 inhibitor), APL-2501 (CLDN6/9 ADC), and APL-2401 (potential best-in-class FGFR2/3 inhibitor) are also progressing steadily [1]